What Palladia Is FDA-Approved to Treat—and What “Used for Other Tumors” Actually Means
Palladia (toceranib phosphate) is FDA-approved in the United States for one labeled use: treating Patnaik grade II or III, recurrent, cutaneous mast cell tumors, with or without regional lymph node involvement, in dogs. The label states that the tablets are for oral use in dogs only. Published reports of toceranib in other tumors or in cats are a different kind of evidence, and they do not make those uses FDA-approved.
What the US label covers
The label's indication reads: "treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs." Each part narrows the use. The tumor must be a mast cell tumor, it must be cutaneous, it must be recurrent, and its Patnaik grade, a pathology classification, must be II or III.
The approval rests on a randomized, placebo-controlled, double-masked field study. It assigned 153 dogs to Palladia (88) or placebo (65) for up to 6 weeks, and the effectiveness analysis included 86 and 63 dogs. The study's measure was objective response, meaning a complete or partial response (at least a 30% decrease in the sum of the longest diameters of target lesions). The objective response rate was 37.2% with Palladia versus 7.9% with placebo (P < 0.001).
The label's study population also marks the boundary of what was tested. Dogs needed at least one tumor of 20 mm or larger, were limited to one completed radiation protocol and one prior systemic chemotherapy regimen, and were excluded if there was evidence of systemic mast cell tumor. The label tells veterinarians to try to rule out systemic mastocytosis before treatment, because a systemic tumor may predispose a dog to serious mast cell degranulation. The label states that safe use has not been evaluated in dogs under 24 months of age or weighing less than 5 kg, and it contraindicates use in breeding, pregnant or lactating dogs.
The label also reports serious risks. It warns of vascular dysfunction that can lead to edema and thromboembolism, and of serious and sometimes fatal gastrointestinal complications, including perforation. It describes a narrow margin of safety in its target animal safety study and reports five deaths in the field study that were possibly drug related. Monitoring, handling and household precautions appear in the label, its Human Warnings and the Client Information Sheet. HERO also has an article on handling Palladia and managing side effects at home, but the label and information sheet are the instructions to follow.
Three buckets for any other use
FDA says there are no FDA-approved cancer treatments for cats. FDA's list of drugs approved to treat cancer in dogs includes Palladia (mast cell tumors, 2009), Stelfonta (mast cell tumors, 2020), Tanovea (lymphoma) and Laverdia (lymphoma). Each has its own label.
How to grade the evidence for a tumor
When someone says Palladia is "used for" another tumor, test the claim against the questions below.
-
Which tumor and which species? A study of anal sac carcinoma in dogs does not describe mast cell tumors in cats.
-
What was the design? A randomized placebo-controlled study, a prospective single-arm study, a retrospective case series and a case report answer different questions. The cat mast cell review compiled cases from specialist listservs, and its authors note that recall bias could inflate the clinical benefit rate.
-
What was the endpoint? The label measured objective response, which means tumor shrinkage. Many reports of other tumors use clinical benefit, which counts stable disease. In the dog solid-tumor study stable disease was assessed over 30 days, and in the cat review it counted if it lasted at least 10 weeks.
-
Was there a comparison group? Without one, a response cannot be separated from the natural course of the disease or from other treatments given at the same time. In the cat review, 70% of cats also received glucocorticoids.
-
What were the harms? The cat review reported adverse events in 60% of cats, mostly low-grade gastrointestinal or blood-count changes, and a small number of liver enzyme increases. The 14-cat cohort reported severe hepatotoxicity in two cats.
-
Who ran it? Studies of toceranib in the sources include authors who received company funding or honoraria, and the dog solid-tumor study used drug provided by the manufacturer. That does not invalidate them, and it is information to weigh.
Early evidence does not guarantee approval. Another kinase inhibitor, masitinib, held conditional FDA approval for canine mast cell tumors, but adequate evidence of efficacy was not demonstrated during the conditional period, and it is no longer available in the United States.
What lawful extra-label use requires
Under the Animal Medicinal Drug Use Clarification Act, extra-label use of an approved drug, meaning use for an unlisted species, indication, dose, frequency or route, must be on the lawful order of a veterinarian within a valid veterinarian-client-patient relationship. FDA states that extra-label use is limited to circumstances in which the animal's health is threatened or suffering or death may result from failure to treat. Extra-label use by a lay person is not permitted except under a veterinarian's supervision, and the extra-label regulation does not permit animal drug compounding from bulk active ingredients.
Even then, the veterinarian is exercising clinical judgment under federal conditions. A report in the literature does not make a tumor use label-equivalent, and no extra-label decision is for an owner to make alone. A published case series of cats also noted that the stability and efficacy of compounded toceranib are unknown.
Questions for the oncologist
Pathology and staging come before a drug discussion, since the label itself depends on the pathology report and on ruling out systemic disease. Bring these questions to the visit.
-
What is the exact tumor type and, for a mast cell tumor, its grade, according to the pathology report?
-
Is the tumor cutaneous and recurrent, and has staging ruled out systemic mastocytosis or spread?
-
Is the proposed use the labeled indication, a published extra-label use, or a use with no published support?
-
If extra-label, which study supports it? Was it randomized, prospective or retrospective, in which species and tumor, and what did it measure?
-
What is the goal: shrinking the tumor, slowing progression, or comfort? How will we judge that it is working?
-
What are the main risks for my pet, given its age, weight, other conditions and medications, and what will we monitor?
-
Are there approved options for this tumor or species, and how do they compare?
-
Who will prescribe and dispense the medication, and what handling precautions apply in my household, including anyone who is pregnant or may become pregnant?
The goal is to leave the visit able to say which bucket the proposed use belongs in, what evidence supports it, and what the oncologist will monitor.